Johnson & Johnson (NYSE:JNJ) will host a business review this morning updating analysts on its pharmaceutical pipeline, including Actelion. Key highlights:
More than 50 regulatory submissions expected by 2021, including 10 with blockbuster ($1B+ sales/year) potential.
Two major launches expected this year: guselkumab for psoriasis and sirukumab for rheumatoid arthritis.
Check, a first-of-its-kind payroll infrastructure startup whose mission is to make paying people simple, announced its public launch today with $35 million in Series B funding from Stripe and Thrive Capital.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated New York attorney Karina E. Murski
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
